1801 (1801) News
Follow 1801 (1801) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Innovent Biologics, Inc. Sets 360 μg/kg RP2D After Phase 1 IBI3003 Update
Innovent reported updated Phase 1 data for trispecific antibody IBI3003 in R/R multiple myeloma and set a 360 μg/kg RP2D, citing rapid, deep responses and a manageable safety profile; Phase 3 TriadicMM-1 in China is ongo
GEOPOLITICS | Sep 29, 2026, 07:47 AM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Innovent Biologics Says Jaypirca (Pirtrobrutinib) Approved In China For Cll/Sll Across All Lines Of Therapy
Innovent Biologics, Inc. HKEX:1801
GEOPOLITICS | Sep 28, 2026, 12:09 PM UTC
L
Jaypirca® (Pirtobrutinib) Approved In China For A New Indication In Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines Of Therapy
Innovent Biologics, Inc. HKEX:1801
GEOPOLITICS | Sep 28, 2026, 10:40 AM UTC
L
Innovent Biologics, Inc. Expands Phase 3 MarsLight-11 to Non-Squamous NSCLC
Innovent expanded its global Phase 3 MarsLight-11 trial of IBI363/TAK-928 in immunotherapy-resistant NSCLC to add a non-squamous substudy, alongside the existing squamous cohort, comparing IBI363 monotherapy vs docetaxel
NEWS | Sep 28, 2026, 12:01 AM UTC
M
US considers rules preserving most pharma licensing deals with China
Sources say the US is working on rules for pharmaceutical investment in China that would likely preserve companies’ ability to strike most licensing deals for Chinese drugs.
REGULATION | Sep 18, 2026, 10:00 AM UTC
L
Taisei Corporation - Notice Regarding Decision Of Supreme Court On Case For Alleged Violation Of Antimonopoly Act
TAISEI CORPORATION TSE:1801
NEWS | Sep 15, 2026, 07:36 AM UTC
L
Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver — Market Talk
Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver — Market Talk
EQUITY | Aug 27, 2026, 06:02 AM UTC